A practical reference on glycyl-histidyl-lysine: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-07-09 and is reviewed periodically as new material appears.
Quality control for GHK-Cu relies on documentation and independent testing rather than a single accepted standard. A certificate of analysis may report peptide purity, copper content, residual solvents, water content, and microbial limits, but the underlying methods and acceptance criteria vary by supplier. Verification can include mass confirmation, amino acid analysis, and comparison with a reference standard when one is available. Open questions include how different copper-binding modes or peptide isomers affect measured activity and whether conventional purity assays capture those differences. Buyers of research-grade material typically need to request raw data rather than rely solely on a summary certificate.
Laboratory characterization of GHK-Cu typically combines separation, spectroscopic, and elemental techniques. Reverse-phase high-performance liquid chromatography is widely used to assess peptide purity, often with ultraviolet detection near the copper-related absorption band or with mass spectrometry for identity confirmation. Because the molecule contains copper, elemental methods such as inductively coupled plasma mass spectrometry or atomic absorption spectroscopy are used to quantify metal content and confirm stoichiometry. No single universal pharmacopeial monograph exists for GHK-Cu. Laboratories therefore validate their own methods, and reported purity values depend on the chosen assay and calibration standards.
Stability of GHK-Cu is influenced by light, oxygen, moisture, pH, and temperature. Solid material is generally kept desiccated and frozen to reduce hydrolysis and oxidation, while aqueous solutions are best prepared fresh or stored cold in aliquots. Repeated freeze-thaw cycles can promote aggregation, precipitation, or peptide degradation. Copper coordination may change under strongly acidic or alkaline conditions, potentially altering the complex's spectroscopic properties. Published long-term stability data for specific matrices, such as cosmetic emulsions or biological buffers, are limited, so shelf-life claims should be treated as formulation-specific rather than universal.
Purity assessment typically involves high-performance liquid chromatography for the peptide and atomic spectroscopy for copper content. The ratio of copper to peptide is a key quality parameter; a value near one indicates proper stoichiometry. Impurities can include free peptide, copper salts, and truncated sequences from synthesis. Because the complex is dynamic, sample preparation and mobile-phase conditions can shift the observed species. Reported purity values therefore depend on the analytical method and should be interpreted with that context.
Characterizing GHK-Cu requires methods that distinguish the intact complex from free peptide and unbound copper. UV-visible absorption around 600 nm provides a rapid check for copper coordination, while circular dichroism reports on peptide secondary structure. Mass spectrometry confirms the peptide mass and can detect copper adducts under carefully controlled conditions. Electron paramagnetic resonance is particularly informative for Cu(II) because it reveals the ligand field symmetry. No single technique fully defines the complex, so laboratories combine orthogonal methods.
Stability of GHK-Cu in solution depends on pH, temperature, buffer composition, and oxygen exposure. The copper center can undergo reduction or dissociation, especially in the presence of strong metal chelators such as EDTA. Aqueous solutions are often prepared fresh or stored frozen to limit degradation. Lyophilized solid is more stable than liquid formulations, but it can absorb moisture and should be kept dry. Light exposure may also affect copper complexes, though the effect is often modest.
| Property | Value | Notes |
|---|---|---|
| Primary identity method | Reverse-phase HPLC with mass spectrometry | Confirms peptide mass and retention behavior |
| Copper quantification | ICP-MS or atomic absorption spectroscopy | Measures metal content and stoichiometry |
| Spectroscopic feature | Visible absorption from copper(II) d-d transitions | Explains blue to blue-violet color |
| Recommended holding condition | Desiccated, protected from light, stored cold | Reduces hydrolysis, oxidation, and moisture uptake |
| Common purity check | HPLC area percent against a reference standard | Values depend on method and standard choice |
Material described in research and cosmetic supply chains is typically a synthetic peptide supplied as a lyophilized powder. Purity is commonly reported through chromatographic separation, often at 95 percent or higher, while copper content is confirmed by separate elemental analysis. Batch variation in color and solubility can reflect residual counter-ions, moisture, or partial oxidation of the peptide. Because the complex is not a single regulatory entity, specifications differ between suppliers and are not standardized internationally.
GHK-Cu is a coordination complex formed between the tripeptide glycyl-L-histidyl-L-lysine and a copper(II) ion. The peptide binds copper through its histidine imidazole nitrogen, its terminal amino group, and a deprotonated amide nitrogen, creating a stable chelate ring. The resulting complex carries a distinctive blue to blue-violet color, which arises from copper d-d electronic transitions. In the solid state it is usually handled as a powder, while in solution the complex can dissociate and re-form depending on pH and competing ligands. The name copper tripeptide-1 is widely used in ingredient listings.
The tripeptide was first isolated from a human plasma filtrate in 1973 during studies of tissue repair factors. Later work detected the free peptide and its copper complex in saliva, urine, and wound fluid, suggesting a natural role in tissue remodeling. Plasma concentrations reported in early literature decline with age, a pattern often cited in discussions of skin aging. Whether these endogenous levels are directly functional or largely incidental remains an open question. The peptide sequence is conserved across mammalian species.
Copper takes part in redox chemistry, and the same property that makes it useful in enzymes can generate reactive oxygen species when the ion is loosely bound. GHK chelates copper through imidazole, amino, and amide nitrogen donors, which reduces the amount of free copper in solution. Whether that chelation is protective, neutral, or harmful in a given tissue is not settled. Laboratory assays report both antioxidant and pro-oxidant behavior, depending on the conditions and the readout used.
Published work on GHK-Cu is dominated by in vitro experiments and small animal studies. Human trials tend to be short and small, with endpoints such as skin appearance rather than clinical outcomes. Review articles often summarize the same underlying laboratory findings, which can make the evidence base look broader than it is. Several basic questions remain open: the concentration of the intact complex in human tissue, the route by which it crosses the skin barrier, and whether effects seen in culture produce measurable changes in people.
Laboratory studies describe GHK-Cu as a source of copper that cells can take up, with reported effects on collagen, elastin, and glycosaminoglycan synthesis in cultured fibroblasts. The peptide also appears in wound-repair research, where it is linked to the activity of matrix metalloproteinases and their inhibitors. These observations come largely from cell and animal models. How directly the complex controls any single pathway in intact human skin remains an open question, and reported effects depend on concentration, vehicle, and exposure time.
Analytical confirmation usually combines a separation method with a copper-specific measurement. Liquid chromatography or mass spectrometry establishes peptide identity and purity, while an elemental measurement quantifies the metal content. A frequent misconception is that any blue solution contains an intact copper peptide complex; color alone does not confirm structure, because free copper salts and degraded mixtures can also appear colored. Literature on efficacy is mixed, with in vitro findings often more dramatic than human evidence, and reviews note small sample sizes and short follow-up. Open questions include optimal concentration, skin penetration, and long-term effects.
Proposed mechanisms for copper peptide activity center on delivery of copper ions to cells and on peptide fragments acting as signaling molecules. Copper is a cofactor for enzymes involved in collagen cross-linking and antioxidant defense, and the peptide may improve its availability at target sites. Separately, the tripeptide and its breakdown products have been reported to influence gene expression in cultured fibroblasts. Much of this evidence comes from laboratory cell cultures and animal models rather than controlled human trials. The relative contribution of the copper ion and the peptide sequence is therefore not fully settled.
Copper binds to the peptide through the histidine imidazole nitrogen and the terminal amino group, forming a stable square-planar complex. Binding constants reported for copper(II) with GHK are high, so the peptide competes effectively for copper in solution. The complex absorbs visible light, which gives solutions a blue to violet colour. Whether the metal-free peptide has a distinct biological function of its own is still an open question; some work treats it mainly as a copper delivery vehicle, while other work reports peptide-specific effects.
The compound was first isolated from human plasma in the 1970s by Loren Pickart, who later described copper-binding activity in liver and other tissues. Early reports focused on its presence in blood and its ability to carry copper between proteins. Commercial and cosmetic use of the term 'copper peptide' has since broadened, and labels rarely distinguish GHK-Cu from other copper-binding fragments. This naming overlap makes literature searching harder, because cosmetic ingredient lists, supplier catalogues and laboratory papers use different vocabularies for the same molecule.
The production of 293Og and its daughter 289Lv, as well as the even heavier isotope 297Og, is also possible using this reaction. The isotopes 295Og and 296Og may also be produced in the fusion of 248Cm with 50Ti projectiles. These heavier and likely more stable isotopes may be useful in probing the chemistry of oganesson. A search in 2017 at RIKEN using this reaction was unsuccessful.
== Clinical significance == Mice with mutant carboxypeptidase E, Cpefat, display endocrine disorders like obesity and infertility. In some strains of mice, the fat mutation also causes hyperproinsulinemia in adult male mice, but this is not found in all strains of mice. The obesity and infertility in the Cpefat mice develop with age; young mice (<8 weeks of age) are fertile and have normal body weight. Peptide processing in Cpefat mice is impaired, with a large accumulation of peptides with C-terminal lysine and/or arginine extensions. Levels of the mature forms of peptides are generally reduced in these mice, but not eliminated. It is thought that a related enzyme (carboxypeptidase D) also contributes to neuropeptide processing and gives rise to the mature peptides in the Cpefat mice. Mutations in the CPE gene are not common within the human population, but have been identified. One patient with extreme obesity (Body Mass Index >50) was found to have a mutation that deleted nearly the entire CPE gene. This patient had intellectual disability (inability to read or write) and had abnormal glucose homeostasis, similar to mice lacking CPE activity. In obesity, high levels of circulating free fatty acids have been reported to cause a decrease in the amount of carboxypeptidase E protein in pancreatic beta-cells, leading to beta-cell dysfunction (hyperproinsulinemia) and increased beta-cell apoptosis (via an increase in ER stress).
== In insects == In Drosophila melanogaster, the alpha-subunit of Na+/K+-ATPase has two paralogs, ATPα (ATPα1) and JYalpha (ATPα2), resulting from an ancient duplication in insects. In Drosophila, ATPα1 is ubiquitously and highly expressed, whereas ATPα2 is most highly expressed in male testes and is essential for male fertility. Insects have at least one copy of both genes, and occasionally duplications. Low expression of ATPα2 has also been noted in other insects. Duplications and neofunctionalization of ATPα1 have been observed in insects that are adapted to cardiotonic steroid toxins such as cardenolides and bufadienolides. Insects adapted to cardiotonic steroids typically have a number of amino acid substitutions, most often in the first extra-cellular loop of ATPα1, that confer resistance to cardiotonic steroid inhibition.
== History == Hyaluronic acid was first obtained by Karl Meyer and John Palmer in 1934 from the vitreous body in a cow's eye. The first hyaluronan biomedical product, Healon, was developed in the 1970s and 1980s by Pharmacia, and approved for use in eye surgery (i.e., corneal transplantation, cataract surgery, glaucoma surgery, and surgery to repair retinal detachment). Other biomedical companies also produce brands of hyaluronan for ophthalmic surgery. Native hyaluronic acid has a relatively short half-life (shown in rabbits) so various manufacturing techniques have been deployed to extend the length of the chain and stabilise the molecule for its use in medical applications. The introduction of protein-based cross-links, the introduction of free-radical scavenging molecules such as sorbitol, and minimal stabilisation of the HA chains through chemical agents such as NASHA (non-animal stabilised hyaluronic acid) are all techniques that have been used to preserve its shelf life. In the late 1970s, intraocular lens implantation was often followed by severe corneal edema, due to endothelial cell damage during the surgery. It was evident that a viscous, clear, physiologic lubricant to prevent such scraping of the endothelial cells was needed.
== Etymology == The proposed name for the toxin is U7-ctenitoxin-Pn1a. Here, 'ctenitoxin' refers to toxins found in the venom of spiders from the Ctenidae family. 'Pn' is an acronym for Phoneutria nigriventer, referring to the genus and species of the animal it was isolated from. A commonly used alternative name for U7-CNTX-Pn1a is PnTx3-5, which is an acronym for Phoneutria nigriventer Toxin 3–5. Here, 3 refers to it being part of the third toxic protein fraction that was isolated from the venom using a technique involving a combination of gel filtration and reverse phase fast protein liquid chromatography. Similarly, 5 refers to it being the fifth peptide that was separated from this fraction through reverse phase and ion-exchange high-performance liquid chromatography.
Sources: en.wikipedia.org
== Actors == John B. Mason (1880), stage actor Ralph Morgan (1904), co-founder of Actors Equity and first president of the Screen Actors Guild Nat Pendleton (1916), portrayer of Eugen Sandow in The Great Ziegfeld and silver-medal wrestler in the 1920 Summer Olympics James Cagney* (1922), winner of the Academy Award for his portrayal of George M. Cohan in Yankee Doodle Dandy Roger De Koven* (c. late 1920s), actor on stage, radio, film and TV; star of Peabody Award-winning radio drama Against the Storm Cornel Wilde* (1933), star of The Greatest Show on Earth, Beach Red, and Academy Award nominee for A Song to Remember Richard Ney (1940), actor, Mrs. Miniver; husband of Greer Garson Dolph Sweet (1948), played Carl Canisky in Gimme a Break! Sorrell Booke (1949), played Boss Hogg in The Dukes of Hazzard Stephen Strimpell (1954), star of Mister Terrific George Segal (1955), star of Who's Afraid of Virginia Woolf?, Ship of Fools and Just Shoot Me!, winner of the Golden Globe Award for New Star of the Year – Actor in 1965 Golden Globe Award for Best Actor – Motion Picture Musical or Comedy in 1973 Brian Dennehy (1960), winner of the Tony Award and the Golden Globe Award for Best Actor – Miniseries or Television Film for Death of a Salesman Don Briscoe (1962), actor, Dark Shadows Roger Davis (1962), actor, Dark Shadows, Alias Smith and Jones William Finley (1963), film actor; co-star of Phantom of the Paradise Jared Martin (1965), actor, Dallas Ben Stein (1966), host of Win Ben Stein's Money; speechwriter for former US President Richard M.
=== Kentucky === In 2005, a bill was introduced that would require 80 hours of didactic and practical training, plus 50 hours of clinical training, and certification as a phlebotomy technician for phlebotomy, that did not pass.
Although they have been determined to be receptors to certain ligands from opioids, their role is not yet fully understood. When opioids are ingested, the ligand binds to these constitutively active receptors to reduce neural activity. This is accomplished by inhibiting adenylyl cyclase and cyclic AMP, which are necessary for communication within the central nervous system. There is research indicating that opioids reduce pain by disrupting ion channels and vesicle fusion. Prolonged exposure to opioids can cause these receptors to become internalized, leading to increased tolerance and increased opioid use.
== History == Following the discovery in 1952 that the tuberculosis drug iproniazid elevated the mood of people taking it, and the subsequent discovery that the effect was likely due to inhibition of monoamine oxidase (MAO) and elevation of monoamine neurotransmitters in the brain, many people and companies started trying to discover monoamine oxidase inhibitors (MAOIs) to use as antidepressants. Deprenyl, the racemic form of selegiline, was synthesized and discovered by Zoltan Ecseri at the Chinoin Pharmaceutical Company (part of Sanofi since 1993) in Budapest, Hungary. Chinoin received a patent on the drug in 1962 and the compound was first published in the scientific literature in English in 1965. Chinoin researchers had been studying substituted amphetamines since 1960, and decided to try synthesizing amphetamines that acted as MAOIs. It had been known that methamphetamine was a reversible inhibitor of MAO. Deprenyl, also known as N-propargyl-N-methylamphetamine, is closely related to and inspired by pargyline (N-propargyl-N-methylbenzylamine), another MAOI that had been synthesized earlier. Deprenyl was initially referred to by the chemical name phenylisopropylmethylpropinylamine and the developmental code name E-250. Work on the biology and effects of E-250 in animals and humans was conducted by a group led by József Knoll at Semmelweis University, which was also in Budapest. Deprenyl is a racemic compound (a mixture of two isomers called enantiomers).
. Express each concentration value as the ratio c/c0, where c0 is the concentration in a [hypothetical] standard state, with a numerical value of 1, by definition. Express the concentrations on the mole fraction scale. Since mole fraction has no dimension, the quotient of concentrations will, by definition, be a pure number. The first and second options above give identical numerical values for an equilibrium constant. Furthermore, since a concentration
Sources: en.wikipedia.org
Identification usually combines reverse-phase high-performance liquid chromatography with mass spectrometry. The copper content can be measured separately by inductively coupled plasma mass spectrometry or atomic absorption spectroscopy. The combination helps distinguish the intact complex from free peptide or free copper.
Light, oxygen, moisture, extreme pH, and elevated temperature can promote degradation or change copper coordination. Aqueous solutions are more vulnerable than dry solid because water enables hydrolysis and oxidation. Freeze-thaw cycling can also reduce sample quality.
A certificate of analysis summarizes tests performed by a supplier, but it does not guarantee that the material is suitable for every use. Methods, limits, and reporting practices differ between laboratories. Independent verification or raw data review is often needed for critical applications.
Peptide content is usually measured by reverse-phase high-performance liquid chromatography, while copper is measured by atomic spectroscopy. Mass spectrometry can confirm the peptide identity and detect copper adducts. Combining these methods gives a more complete picture.